title: The efficacy of milbemycin oxime against pre-adult Spirocerca lupi in experimentally infected dogs.
abstract: The aim of this investigation was to determine the efficacy of milbemycin oxime in preventing the oesophageal encapsulation of Spirocerca lupi, following the experimental infection of dogs. Two studies were conducted which involved a total of 21 purpose-bred Beagles. Each dog was infected with approximately 40, third stage infective S. lupi larvae. The larvae were dissected from scarabaeid beetles that had been collected from areas endemic for spirocercosis. In the first study, milbemycin oxime (minimum dose 0.5mg/kg body weight) was administered to seven dogs on day 30 post-infection. Seven other dogs served as untreated controls. In the second study, milbemycin oxime (also at a minimum dose of 0.5mg/kg body weight) was administered to four of seven infected dogs on day 28 post-infection. Treatment was repeated at 14- or 28-day intervals. All of the dogs, from both studies, were euthanized 168 or 169 days after infection. All S. lupi were recovered, and lesions in the thoracic aorta and oesophagus were described and quantified. A single treatment with milbemycin oxime was 79.8% effective in preventing the establishment of S. lupi in the oesophagus. This treatment significantly (p<0.05) reduced both the number of S. lupi within the oesophagus and the size of the oesophageal nodules. The efficacy of anthelmintic treatment was increased to 100% when repeat doses of milbemycin oxime were administered at 14- or 28-day intervals. These repeat treatments completely prevented the establishment of S. lupi within the oesophagus and thereby averted the development of oesophageal nodules. As expected, none of the treatment protocols reduced S. lupi related damage within the aorta because the administration of milbemycin oxime only began after the larvae had completed their first stage of migration.
authors.affiliation: ClinVet International, PO Box 11186, Universitas, Bloemfontein 9321, South Africa. dawie@clinvet.com
authors.forename: D J
authors.initials: DJ
authors.lastname: Kok
authors.forename: R
authors.initials: R
authors.lastname: Schenker
authors.forename: N J
authors.initials: NJ
authors.lastname: Archer
authors.forename: I G
authors.initials: IG
authors.lastname: Horak
authors.forename: P
authors.initials: P
authors.lastname: Swart
mesh_terms: D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy* / Q000469:parasitology / Q000473:pathology; D004285:Dogs; D004338:Drug Combinations; D005260:Female; D018942:Macrolides / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D011223:Praziquantel / Q000008:administration & dosage / Q000627:therapeutic use; D017205:Spirurida Infections / Q000188:drug therapy / Q000469:parasitology / Q000473:pathology / Q000662:veterinary*; D013802:Thelazioidea / Q000145:classification*
chemical_list: D004338:Drug Combinations; D018942:Macrolides; C078973:milbemycin oxime; D011223:Praziquantel